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epigenetic silencing stems from studies of globin gene regulation. As discussed
here, the term epigenetics refers to postsynthetic modifications of DNA and chro-
mosomal histone proteins that affect gene expression and can be inherited through
somatic cell replication. A full understanding of the molecular mechanisms of
epigenetic silencing of HbF expression should facilitate the development of more
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Table I. Developmental stage-specific human and
mouse b-type globin gene and corresponding
hemoglobin expression patterns
Species
Developmental
stage
Predominant b-type globin
(hemoglobin)
Mouse Primitive bH1, εg (Hb E) I-III
Definitive bmaj (Hb bmaj)
bmin (Hb bmin)
Human Primitive ε (Hb Gower-1, Hb Gower-2)
Definitive
Fetal gestational and ɣ (HbF), (Hb Portland-1)
Postpartum b (HbA)
d (HbA2)
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DNA methylation was the first well-described epige-
netic signal and was long posited to have a role in gene
regulation.1-3 Vertebrate globin genes were among the
first in which an inverse relationship between cytosine
methylation and transcription was demonstrated.4-7
Both histone and nonhistone chromosomal proteins
after synthetic modifications have also been shown to
have important roles in gene regulation, a concept
formalized as the histone code.8-10 These relationships
have been described in detail in a review elsewhere.11
The current discussion will focus primarily on the
epigenetic mechanisms involved in developmental
human b-type globin gene silencing (and hence fetal
hemoglobin [HbF] silencing) and the preclinical and
potential clinical translational avenues for overcoming
this silencing in context of the treatment of inherited
b-globin gene disorders.
In all vertebrates that have been studied, a switch
from embryonic, or primitive, to definitive hemoglo-
bin production occurs in erythroid cells during devel-
opment. In humans and old world primates, as well
as certain ruminants, an intermediate HbF predomi-
nates during mid to late gestational stages and per-
sists at a low level postpartum in definitive
erythroid cells after adult hemoglobin predominates
(Table I). The details of this switch have been
reviewed extensively.12,13
As with much of human biology, the ability to identify
important regulatory mechanisms that are physiologi-
cally relevant is a major challenge requiring robust
preclinical models for understanding ɣ-globin gene
silencing in adults and successfully targeting those
mechanisms therapeutically. Because of a high degree
of evolutionary conservation of gene regulatory mecha-
nisms in erythroid cells, transgenic mice bearing a yeast
artificial chromosome (YAC) containing an intact hu-
man b-globin gene locus (b-globin YAC) have provided
a valuable model system for studying developmental
globin gene regulation. The transgenic mouse model
also allows for testing the effects of modulating epige-
netic processes in the context of whole animal physi-
ology. At the same time, the b-globin YAC mouse
model is limited by the fact that the mouse lacks a
true analog of the human fetal erythroid compartment,
such that the transgenic human ɣ-globin gene is regu-
lated like the murine embryonic b-type globin genes,
which are repressed several orders of magnitude more
than the human ɣ-globin gene in adult humans14
(Table 1).
Cultured primary human erythroid cells derived from
CD341 progenitors induced to erythroid differentiation
provide another powerful model for studying humanɣ-globin gene silencing.15,16 The limitations of cul-
tured primary erythroid cells include their limited life
span, and the fact that achieving terminal erythroid
differentiation while maintaining cell viability is often
challenging.
The primate baboon model also has been quite useful
given that the developmental b-type globin gene reper-
toire of the baboon is very similar to humans, including
an HbF.17 Other vertebrate models and cultured cell
systems have provided important early insights into
epigenetic control of globin gene silencing, but this dis-
cussion of preclinical translational studies is directed
primarily at the aforementioned models.
Much of the focus of research on developmental
ɣ-globin gene silencing has been on trans-acting tran-
scription factors. The discovery of the quantitative trait
locus B-cell lymphoma-leukemia A (BCL11A) on chro-
mosome 2p1618,19 identified this factor as an important
regulator of HbF expression. Subsequent studies have
shown that BCL11A binds to an intergenic region in
the b-globin locus and has a dominant silencing effect
on murine embryonic b-type bH1 and εg-globin, as well
as human ε- and ɣ-globin gene expression in b-YAC
transgenic mice.12,20
Knockdown of BCL11A in cultured primary human
adult erythroid cells also results in a significant upregu-
lation of ɣ-globin gene expression, although the magni-
tude of this effect is much less than in the b-YACmouse
model.19 The transcription factor SOX6 also mediates
embryonic bH1 and εg-globin gene silencing in the
mouse, and it is known to interact with BCL11A.21,22
Kr€uppel-like factor 1(KLF1), originally known as
erythroid KLF, EKLF was initially shown to be critical
for adult b-globin gene transcription,23 and to increase
the ability of the b-globin promoter to compete with
the ɣ-globin promoter for the enhancer function of
the erythroid-specific b-globin locus control region.24,25
A more direct role of KLF1 in ɣ-globin gene silencing
occurs through its stimulation ofBCL11A expression.26,27
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HbF levels through both quantitative trait locus studies
and functional assays.18,28-30
A number of other transcription factors have been
implicated in embryonic-fetal b-type globin gene
silencing. These include transcription factor that binds
to the DNA sequence GATA (GATA1) in association
with FOG1 and the nucleosome remodeling and deace-
tylase (NuRD) complex,31-34 nuclear factor erythroid
4 (NFE4),35 the TR2/TR4/direct repeat erythroid defin-
itive (DRED) complex,36,37 Ikaros in association with
the SWI/SNF-related protein complex coregulatory
complex.38
As the transcription factors involved in fetal globin
gene silencing have been recently reviewed, the remain-
ing part of this reviewwill focus primarily on epigenetic
silencing mechanisms.39EPIGENETIC REGULATORS—WRITERS AND READERS
There are only a few examples in which an epigenetic
modification of DNA or a chromosomal protein has a
direct effect on structure or function.40 An exception
is histone acetylation, which does appear to directly
alter chromatin structure.11,41 In most cases, epige-
netic marks serve as a recognition signal for a protein
or protein complex, which ultimately carries out the
specific associated regulatory function. A useful orga-
nizing concept for identifying potential targets for
perturbing epigenetic fetal globin gene silencing is
that of writers and readers. Writers are the enzymes
that deposit or remove an epigenetic mark, whereas
readers are the proteins or complexes that interpret
those marks and carry out the associated regulatory
function.DNA METHYLATION
DNA methyltransferase (DNMT) is a major category
of epigenetic writers, as DNA methylation was the
first well-established epigenetic regulatory signal.
The most well characterized of these are the de novo
methylases, DNMT3A, and DNMT3B, which sym-
metrically methylate cytosines in the dinucleotide
Cytosine-phosphate-Guanine (CpG) on both strands of
unmethylated DNA, and DNMT1, a so-called mainte-
nance methylase, that adds a methyl group to the sym-
metric CpG on the unmethylated strand of DNA after
DNA replication. From the time of the discovery that
silent embryonic and fetal b-type globin genes are
methylated and that the cytidine analog, 5-azacytidine,
inhibits the processive methylation of hemimethylated
DNA after replication, many studies have focused
on DNMT1 as a target for reversing globin gene
silencing. Initial studies in animal models42 werefollowed by clinical interventions that demon-
strated increased HbF expression in patients with
both sickle cell anemia and b-thalassemia who were
treated with 5-azacytidine.43-45 The mechanism by
which 5-azacytidine actually induces increased human
fetal gamma globin gene expression has been debated,
and mechanisms such as generalized cytotoxicity
and induced erythroid cellular stress have been
proposed.13,46-50 Nonetheless in well-characterized pri-
mate and human b-globin gene locus-bearing trans-
genic mouse models, disruption of DNA methylation
appears to be a major mechanism of relieving ɣ-globin
gene silencing, although perhaps indirectly in part.51-56
Despite the development of more specific inhibi-
tors of DNMT1, such as decitabine, which, unlike
5-azacytidine, lacks effects on RNA metabolism,
concerns about the safety of this class of agents have
limited clinical application in b-hemoglobinopathies.
However, a recent study of low dose decitabine in
b-thalassemia patients reported an increase in HbF
without detectable short-term cytotoxicity or geno-
toxicity.57
The readers of DNA methylation are a group of pro-
teins that preferentially bind to DNA containing sym-
metrically methylated CpG dinucleotides. The largest
family of these are the methylcytosine-binding domain
(MBD) proteins, which include MBD1, MBD2,
MECP2, and MBD4.58 Of these, the role of MBD2 in
regulating embryonic/fetal b-type globin gene silencing
in adult erythroid cells is the most well characterized.
MBD2 binds preferentially to DNA containing a high
density of methylated CpGs. MBD2 has been shown
to bind directly to the avian embryonic r-globin gene,
and knockdown of MBD2 derepresses the gene in adult
erythroid cells in culture.59 Knockdown of MBD2 has
also been shown to induce a large increase in expression
of the silent human ɣ-globin gene in human b-globin
locus–bearing transgenic mice53 and in human primary
CD34 precursor–derived adult erythroid cells.60 Impor-
tantly, complete knockout of MBD2 in transgenic mice
does not result in any major deleterious phenotype,61
suggesting that its disruption postnatally in somatic
cells may have minimal toxicity.
MBD2 mediates silencing by recruiting the NuRD
complex to methylated DNA.62,63 Structural studies of
the MBD2-NuRD complex have identified a critical
coiled-coil protein interaction between MBD2 and
p66a/b, another NuRD complex component. Enforced
expression of the p66 coiled-coil protein results in
release of the Mi2b chromatin remodeling ATPase
from the NuRD complex, and derepression of the
silenced embryonic and fetal b-type globin genes, pre-
sumably by decoupling MBD2 from the NuRD chro-
matin remodeling function.60
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MBD3, also associates with a NuRD complex, but
does not bind to methylated vs nonmethylated DNA
with high affinity.58,64 Moreover, the presence of
MBD2 and MBD3 in association with NuRD complex
appears to be mutually exclusive.65 MBD3-NuRD is
associated with the ɣ-globin gene promoter primarily
through association with the GATA1 transcription fac-
tor–associated protein, friend of GATA1 (FOG1),32,33
or other complexes.66 Disruption of expression of the
Mi2b subunit of NuRD results in increased ɣ-globin
gene expression in transgenic mice,34 cultured mouse
chemical inducer of dimerization (CID) hematopoietic
cells bearing a human b-globin gene locus, and cultured
primary human erythroid cells.67
Recently, it was shown that as little as a 50% knock-
down of Mi2b in primary human erythroid cells results
in a 10-fold increase in ɣ-globin gene expression
without affecting erythroid differentiation, compared
with control CD341 progenitor–derived erythroid cells
treated with scramble short hairpin RNA.67 The degree
of differentiation in control cells in these studies leads to
a level of 1% ɣ/ɣ1b RNA, which is comparable with
normal adult reticulocyte levels. Interestingly, in these
studies, the effect of Mi2b on ɣ-globin gene silencing
did not appear to be chiefly because of an effect on
MBD2-NuRD or MBD3-NuRD. Rather at least part of
the effect was through downregulation of BCL11A
and KLF1 in Mi2b knockdown erythroid cells. The pur-
posed relationships of MBD2-NuRD, MBD3-NuRD,
and Mi2b in ɣ-globin gene silencing in the context of
other major epigenetic regulatory factors are depicted
in Fig 1.67 On the basis of the preponderance of evi-
dence, it appears that MBD2 plays a greater role than
MBD3 in silencing ɣ-globin gene expression, whereas
Mi2b plays a greater role than either MBD2 or MBD3.HISTONE ACETYLATION
Increased histone acetylation has long been posited
to be associatedwith decompressed chromatin and active
gene expression.68,69 The writers for histone acetylation
are histone acetyltransferases including P300/CBP
(CRE3 binding protein), PCAF, and TAF(11)250 (TBP
associated factor),70 as well as histone deacetylases
(HDACs, which might be more properly thought of as
‘‘erasers’’). The complexity of histone acetylation and
its relationship to gene regulation have been intensively
studied and will not be reviewed in detail here. The
consensus is that acetylation of lysines at histone tails
results in charge neutralization and loosening of the
interaction of nucleosomes with their associated DNA.11
A number of inhibitors of HDACs have been identified
or synthesized, the prototype being butyric acid.69Butyric acid and derivatives were shown to induce the
expression of silenced embryonic and fetalb-type globin
genes in several animal models.71,72 Although increased
HbF expression was associated with increased histone
acetylation in the vicinity of the ɣ-globin gene,54 it is
important to recognize that HDACs might potentially
affect acetylation of transcription factors and other
nonhistone proteins. Moreover, butyrate and other
HDAC inhibitors have been shown to affect other sig-
naling pathways including the Signal Transducer and
Activator of Transcription 5, cyclic Adenosine Mono-
phosphate, and Mitogen Activated Protein kinase
systems.73-75 Thus, the exact molecular mechanisms
of ɣ-globin gene activation by HDAC inhibitors are not
fully known. Nonetheless, treatment of patients with
sickle cell anemia and b-thalassemia with sodium
butyrate and butyric acid was shown to induce in-
creased HbF expression.76,77 The effect of naturally
occurring butyrates is somewhat variable, possibly
reflecting phenotypic differences in their metabolism
or in the factors that are responsible for the mech-
anisms of action. Extensive efforts have been made
to improve on the effectiveness of HDAC inhibi-
tors, whereas decreasing unwanted adverse effects.
Recent large-scale chemical genetic studies indepen-
dently identified HDAC1 and HDAC2 inhibitors as
inducers of ɣ-globin gene expression,78 affirming the
likely mechanism of action of butyric acid and its
derivatives.HISTONE METHYLATION
Unlike histone acetylation, which is generally asso-
ciated with both active chromatin configuration and
gene expression, histone methylation can signal gene
activation, gene silencing, or a bivalent state. For
example, histone H3K4me3 methylation is usually
associated with open chromatin and gene transcription,
whereas histone H3K9 and H3K27me3 methylation are
most frequently associated with gene silencing.8,79,80
The presence of both H3K4me3 and H3K27me3 is
associated with a poised bivalent state.81
The major writers of histone methylation are
the SUV, Enhancer of zeste, Trithorax protein (SET)
domain lysine–specific methylases and the protein
arginine methyltransferases (PRMTs). A PRMT5-
dependant multiprotein complex has been shown to
contribute to human ɣ-globin gene silencing. Moreover,
symmetric methylation of histone H4 arginine 3 (H4R3
Me2s) serves as a binding target for DNMT3A leading
to methylation at the ɣ-globin gene promoter. The his-
tone lysine methyltransferase Suv4-20h1 and compo-
nents of the NuRD complex are also associated with
these complexes.66,82 Recently, the methyltransferase
Fig 1. Mi2b-mediated epigenetic globin gene silencing through multiple mechanisms. Mi2b is a critical compo-
nent of the MBD2/NuRD complex, which regulates developmental globin gene silencing independently of
BCL11A and KLF1/EKLF. Mi2b also binds to the distal promoter region of the g-globin gene as part of the
MBD3/NuRD/GATA-1/FOG-1 silencing complex. Importantly, Mi2b binds to and activates expression of
BCL11A and KLF1/EKLF, which in turn silence ɣ-globin gene expression. In each of these processes, Mi2b
has been shown to directly promote ɣ-globin gene silencing. As depicted, Mi2b is also associated with the
BCL11A complex and the TR2/TR4/DRED complex through its association with NuRD, but as indicated by
the noncolored symbol, its role in the activity of these complexes has not been demonstrated directly. Likewise,
other noncolored symbols designate epigenetic modulators that have not been shown directly to mediate silencing
in association with factors designated by colored (shaded) symbols. BCL11A, B-cell lymphoma/leukemia A;
CoREST, REST-co-repressor; DNMT, DNAmethyltransferase; EKLF, erythroid Kr€uppel-like factor; HSS, DNase
I hypersensitive site; KLF, Kr€uppel-like factor; LCR, locus control region; LSD, lysine-specific demethylase;
MBD, methylcytosine-binding domain; N-COR, nuclear receptor co-repressor 1; NuRD, nucleosome remodeling
and deacetylase; PRMT, protein arginine methyltransferase; SMRT, silencing mediator for retinoid and thyroid
receptors. For interpretation of the references to color in this figure legend, the reader is referred to theweb version
of this article.
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shown to induce ɣ-globin gene expression in human
primary erythroid cells in culture, suggesting that
PRMT5 enzymatic activity may be mechanistically
linked to silencing. Given the possible off target
effects of inhibitor studies, the possibility remains that
the effects of Adox may be through another methyl-
transferase.83
Another member of the PRMT family, PRMT1, has
been associated with human ɣ-globin gene silencing
through association with a protein named friend of
PRMT1 (FoP).84 Knockdown of FoP protein resulted
in increased ɣ-globin gene expression in cultured
primary human erythroid cells. Interestingly, PRMT1
has also been shown to facilitate a number of histone
acetylation events including acetylation of Lys9/Lys14
and subsequent transcription of the adult b-globingene.85 This result suggests that the enzymatic activity
of PRMT1 also may contribute to ɣ-globin gene
silencing through increasing the b-globin gene’s ability
to compete for the b-globin locus control region
enhancer activity.
Specific lysine demethylases are involved in ɣ-globin
gene silencing in both murine and human
adult erythroid cells. The lysine-specific demethylase 1
(LSD1) has been shown to associate with the transcrip-
tion factor BCL11A through a complex containing
the repressor element-1 silencing factor corepressor-1
(CoREST),86 and to mediate part of BCL11A’s strong
ɣ-globin gene silencing activity. LSD1 also has been
shown to associate with the TR2/TR4/DRED complex,
alongwith several other corepressor complexes.87 Inhibi-
tion of LSD1 by either RNA interference or the LSD1
enzymatic activity inhibitor, tranylcypromine, results
Fig 2. Interdependence of epigenetic gene silencing. Existing data suggest that DNA methylation and postsyn-
thetic histone modification are dependent on one another and in turn reinforce each other. Either mark appears
capable of establishing the other by recruiting epigenetic writer enzymes, thus resulting in a cycle that reinforces
gene silencing. For example, as illustrated, DNA methylation recruits methylcytosine-binding proteins, which
recruit corepressor complexes that contain histone-modifying enzymes that catalyze loss of activating marks
(eg, histone acetylation and methylation) or addition of repressive marks (eg, histone methylation). In turn, repres-
sive histone modifications such as H3K9 methylation can recruit DNMTs that deposit the repressive methylation
mark at CpG dinucleotides. DNMT, DNA methyltransferase; HDAC, histone deacetylase; LSD, lysine-specific
demethylase; MBD, methylcytosine-binding domain; NuRD, nucleosome remodeling and deacetylase; PRMT,
protein arginine methyltransferase.
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bearing transgenic mice and cultured primary human
erythroid cells.86,88 However, because LSD1 is required
for normal erythroid maturation, it has been suggested
that its inhibition potentially might adversely affect that
process.86THE INTERPLAY BETWEEN DNA METHYLATION AND
HISTONE MODIFICATION IN REGULATING GENE
EXPRESSION
Studies in vertebrate model systems have demon-
strated a close and often reinforcing relationship
between DNA methylation and repressive histone modi-
fications in gene silencing.89,90 In some instances, DNA
methylation and associated methyl-binding domain pro-
teins recruit corepressor complexes that contain SET
domain proteins, which catalyze H3K9 methylation.91
Other studies have demonstrated that repressive histone
marks such as H3K9 methylation may recruit DNMTs.92
Conversely, histone acetylation has been shown to pre-
vent extinction of gene expression and subsequent
DNA methylation.41,93 The often self-reinforcing nature
of these interactions is depicted in Fig 2.microRNA AND RNA INTERFERENCE
Frequently microRNA (miRNA) and small in-
hibitory RNA are included in the category of epige-
netic regulatory mechanisms. These small RNAs
are capable of well-characterized post-transcriptional
gene silencing, but also have been shown to direct
epigenetic modifications in plants and animals.94
Several miRNAs have been implicated in the regula-
tion of ɣ-globin gene expression. LIN28B and the
associated let-7 miRNA family are regulated during
fetal to adult erythroid development. Enforced expres-
sion of LIN28B resulted in increased ɣ-globin gene
expression in cultured adult primary human erythroid
cells, whereas LIN28B knockdown decreased ɣ-globin
gene expression in fetal cord blood–derived human
erythroid cells which normally express high levels
of HbF.95 At least part of this effect was attributed
to the effect of LIN28B on expression of BCL11A.
Similarly, microRNA-486-3p was shown to bind
to the BCL11A messenger RNA 30-untranslated re-
gion and downregulate its expression concomi-
tant with upregulation of ɣ-globin gene expression
in cultured human erythroid cells.96 The role of
Table II. Association of ɣ-globin gene silencing
transcription factors with epigenetic modulators
Transcription factors Associated epigenetic modulators
BCL11A MBD3-NuRD (HDAC1/2),* CoREST,*
NCoR/SMRT,* LSD1,* Sin3A,*
DNMT1,* Mi2b/CHD4†
TR2/TR4 MBD3-NuRD (HDAC1/2)*
LSD1,* Sin3A,* DNMT1*
GATA1/FOG1 MBD3-NuRD (HDAC1/2)*
NFE4 DNMT3A*
KLF1 BRG1/SWI/SNF,* Mi2b/CHD4†
Ikaros SWI/SNF*
Abbreviations: BCL11A, B-cell lymphoma/leukemia A; CoREST,
REST-co-repressor; DNMT, DNA methyltransferase; HDAC, histone
deacetylase; KLF1, Kr€uppel-like factor 1; LSD1, lysine-specific de-
methylase 1; MBD, methylcytosine-binding domain; Mi2b/CHD4,
chromodomain helicase DNA–binding protein 4; NCoR/SMRT,
nuclear receptor co-repressor-1/silencing mediator for retinoid
and thyroid receptors; NuRD, nucleosome remodelinganddeace-
tylase; PRMT, protein arginine methyltransferase.
*The epigenetic modulator factor acts as effectors of transcription
factor-mediated silencing.
†The epigenetic modulator factors may act to regulate expression
of a specific transcription factor.
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or microRNA-486-3p remains unknown.
INTERPLAY BETWEEN TRANSCRIPTION FACTORS AND
EPIGENETIC REGULATORS
Any discussion of epigenetic regulation of globin
gene expression must account for the interplay between
transcription factors and coregulatory complexes with
which they interact and which in turn often contain
both ‘‘writers’’ (eg, histone acetylases and deacetylases),
and ‘‘readers’’ (eg, methylcytosine-binding proteins) of
epigenetic chromatin marks. Several transcription fac-
tors that are involved in embryonic fetal b-type globin
gene silencing are known to associate with one or
more corepressor complexes. Among these, BCL11A
has emerged as a dominant regulator of developmental
globin gene silencing in mice and is also implicated as
a strong mediator of ɣ-globin gene silencing in cul-
tured human primary erythroid cells.19 BCL11A has
been shown to associate with the MBD3-NuRD com-
plex, as well as the LSD1/CoREST complex, Sin3A,
NCoR/SMRT, and DNMT1.86 Another transcription
factor complex associated with embryonic globin gene
silencing, the TR2/TR4/DRED orphan nuclear receptor
complex, has been shown to associate with a number
of epigenetic coregulatory proteins, including the
MBD3-NuRD, LSD1/CoREST, Sin3A complexes, and
DNMT1.87 Thus, the effectors of these transcription
factors may be in large part epigenetic.
Another connection between epigenetic regulators
and transcription factors that are involved in ɣ-globin
gene silencing is through epigenetic regulation of
expression of the transcription factors themselves. It
was recently shown that Mi2b/CHD4 (chromodomain
helicase DNA–binding protein 4), independently of
the NuRD complex, is required for high level expression
of both KLF1 and BCL11A in primary human adult
erythroid cells and that Mi2b/CHD4 binds directly to
BCL11A67 (see Fig 1).
It is important to note that virtually all the epigenetic
and transcriptional regulatory factors that are discussed
here and depicted in Fig 1 have been shown to play a
role in normal developmental globin gene switching.
However, the relative effect of a given factor in the total-
ity of ɣ-globin gene silencing appears to vary consider-
ably in developmental globin silencing or ‘‘switching’’
vs maintenance of silencing in the adult erythroid
compartment.
A summary of the coregulatory complexes that
contain known epigenetic readers and writers and that
are associated with transcription factors involved in
developmental regulation of ɣ-globin gene expression
is presented in Table II.TRANSLATIONAL CLINICAL TRIALS TARGETING
EPIGENETIC HBF SILENCING
The first clinical trials aimed at reversing
HbF silencing in patients with sickle cell anemia
and b-thalassemia targeted DNA methylation with
5-azacytidine.43-45 Although subsequent trials with
cytotoxic agents raised questions as to the exact
mechanism of 5-azacytidine–induced HbF expression,13
a number of preclinical studies support a major role for
DNA hypomethylation.51-53,55,56 As noted previously,
concerns about adverse effects of hypomethylating
agents with known cytotoxicity have limited the
widespread use of 5-azacytidine and decitabine in the
clinic.
The use of HDAC inhibitors represents the other ma-
jor example of clinical trials aimed at targeting epige-
netic silencing of HbF expression in patients with
b-globin gene disorders.76,77,97 Recent trials with oral
butyrate derivatives have shown activity in patients
with b-thalassemia. One such agent sodium 2,2-
dimethyl butyrate was shown to be tolerated in phase
I/II trial.98 Although butyrate and derivative compounds
have demonstrated effectiveness in some patients,
the effects are variable. The nature of this variability
remains unknown and could involve differences in
metabolism of various HDAC inhibitors or genetic het-
erogeneity in acetylated protein targets or downstream
regulatory factors in different patients.
On the basis of the preclinical studies described
previously, a number of epigenetic modulators are
Table III. Potential epigenetic therapeutic targets
of ɣ-globin gene silencing
DNA methyltransferases
Histone deacetylases
Histone demethylases
Methyl-CpG-binding domain protein 2
Mi2b/CHD4 ATPase chromatin remodeler
Protein arginine methyltransferase 5
Friend of protein arginine methyltransferase 1
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are being planned. Among these are inhibitors of the
histone lysine demethylase, LSD1,86,88 the histone
arginine methylase, PRMT5,83 and selective HDAC1
and HDAC2 inhibitors.78 The development of more
selective HDAC inhibitors may increase their effective-
ness, whereas decreasing the unwanted adverse effects
of these agents.
In the face of a large number of epigenetic targets for
inducing HbF expression in patients with b-thalassemia
and sickle cell anemia, consideration of several factors
should guide the further development of targeting stra-
tegies. The same considerations also apply to therapeu-
tic targeting of transcription factors such as BCL11A
and KLF1. The first is selection of the most informative
preclinical model systems to identify promising agents.
Human b-globin locus–bearing transgenic mice have
provided a valuable model to identify important epige-
netic and transcription factor silencers of embryonic/
fetal b-globin gene expression. However, as noted
previously, because mice only have embryonic and
adult b-globin expression, this model may either under-
estimate or overestimate the effect that a given epige-
netic or genetic fetal globin gene silencer will have
in humans.
Cultured human primary erythroid cells derived from
CD341 progenitors also provide a valuable model for
identifying epigenetic targets for inducing HbF expres-
sion. One important caveat for studies using these cells
is that it is very important that the level of ɣ-globin gene
expression be measured after extensive erythroid differ-
entiation when the ɣ/ɣ1b expression level in control
cells approaches that in normal adult erythroid cells.
Agents that interfere with differentiation might result
in a sufficient increase in ɣ-globin gene expression in
this model to be clinically useful, but may have delete-
rious effects on erythropoiesis. Variation in the level of
erythroid differentiation achieved in studies of agents
that disrupt ɣ-globin gene silencing in this cell model
system must be taken into consideration when assessing
their relative therapeutic potential.
Another consideration is how specific the effect of a
given type of epigenetic targeting might be. Clearly
epigenetic regulatory factors have global effects on
gene expression in all cell types, so that complete inhi-
bition or ablation would likely be catastrophic in many
instances. One exception might be the methyl-binding
domain protein MBD2, whose complete absence is
tolerated in knockout mice with only a minimal pheno-
type.63 It is also generally believed that only genes that
are in a poised state can be readily transcriptionally acti-
vated. Thus, if partial inhibition of multiple fetal globin
gene silencing mechanisms can be achieved epigeneti-
cally, this might be highly effective with acceptableshort- and long-term off target effects. Finally, the feasi-
bility of targeting a given epigenetic regulator must be
considered. Those that function through enzymatic
activity such as DNA methylases, HDACs, histone
demethylases, and histone methylases, and potentially
the ATPase activity of Mi2b/CHD4, are more readily
druggable. This is largely why clinical trials targeting
these regulators already have been carried out or are
underway. Like transcription factors, those epigenetic
regulators such as MBD2-NuRD that function through
protein-protein or protein-DNA interactions have been
considered ‘‘undruggable’’ in the past. However, recent
success in developing agents, such as covalently stapled
peptides capable of disrupting protein-protein interac-
tions in animal models,99-101 and targeting specific pro-
teins for degradation in the proteasome102,103 suggest
that this class of epigenetic regulators may be targeted
successfully in the future (Table III).
CONCLUSION
Epigenetic mechanisms play a key role in fetal globin
gene silencing, both independently and in cooperation
with specific transcription factor silencers such as
BCL11A and KLF1. Among the first proof of principle
targeted treatment trials in patients with b-hemoglobin-
opathies were those aimed at DNAmethylation and his-
tone acetylation, 2 key epigenetic marks of globin gene
transcriptional activity. With further understanding of
the specificity of epigenetic fetal globin gene silencing
mechanisms, it is likely that targeting of this process
will result in more successful treatment of patients
with b-globin disorders through the induction of
increased HbF levels.ACKNOWLEDGMENTS
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